Allied Health & Imaging · Independent exam preparation
Certified Principal Investigator (CPI®) Preparation Guide Study Guide
Practise investigator decisions in trial design, participant protection, safety reporting, site oversight, product accountability and reliable research data.
By CertMedbry · Updated 30 October 2026
Practise deciding whether a trial is feasible, whether consent remains valid, how to evaluate safety information, and how to protect reliable study data. This selective guide develops 60 concepts across all six domains of the current linked 2024 CPI Examination Content Outline. The official outline, including its knowledge areas and task statements, defines the full scope. The guide follows the international guideline references applicable after ACRP's July 15, 2026 transition to ICH E6(R3).
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which current examination does this guide prepare for?
The Certified Principal Investigator (CPI®) Examination, administered by the Academy of Clinical Research Professionals, an independent affiliate of ACRP. The current designation is Principal Investigator; the historical Physician Investigator wording should not be used to restrict the current credential to physicians.
CPI Certification — ACRP · The Academy — ACRP · Clinical Researcher, February 2015 — One Word and One World of Difference
How many questions are on the examination, and how long is allowed?
ACRP's CPI page specifies 125 multiple-choice questions and a 180-minute limit.
What delivery method, adaptivity and item styles are verified?
ACRP offers both in-person and remote examination scheduling. The documented item style is multiple choice; adaptivity and additional item formats remain unverified. The 20 questions here are independent four-option, single-best-answer drills; they do not reproduce a testing platform or predict a passing result.
Which blueprint and domain allocations apply?
The currently linked outline is labeled 2024 and was checked again on October 30, 2026. It states no separate effective date. Its allocations total 100: Scientific Rationale and Principles of Research Design 15%; Ethical and Safety Considerations 22%; Product Development and Regulation 12%; Clinical Trial Operations 21%; Study and Site Management 17%; and Data Management 13%. This guide allocates its 60 concepts as 9, 13, 7, 13, 10 and 8. Questions and flashcards each use 3, 4, 2, 4, 4 and 3.
Which guideline version and jurisdictional scope should candidates use?
ACRP replaced ICH E6(R2) with E6(R3) for its examinations on July 15, 2026. That examination transition differs from ICH's January 6, 2025 adoption of the final guideline. ACRP lists international references including E2A, E8(R1), E9, E9(R1), E11(R1) and the Declaration of Helsinki; country-specific regulatory frameworks are excluded from the examination reference scope. Actual study conduct still requires compliance with applicable local requirements.
CPI Certification — ACRP · Frequently Asked Questions — ACRP · ICH E6(R3) Guideline for Good Clinical Practice
How does the historical CCRI designation relate to CPI?
An ACRP-hosted 2012 account identifies ACRP's earlier Certified Clinical Research Investigator designation and describes consolidation into Certified Physician Investigator around 2006. The historical APPI guide records the first integrated examination on March 11, 2006. ACRP's February 2015 publication documents the later change from Certified Physician Investigator to Certified Principal Investigator. Historical outlines and eligibility rules are not substituted for the current CPI outline.
CPI Certification as Predictor of Clinical Investigators' Regulatory Compliance · CPI Certification Guide — March 2009 · Clinical Researcher, February 2015 — One Word and One World of Difference
Does this guide cover every program using the CCRI label?
No. Pharma Research pages also describe a separate SoCRP offering using CCRI terminology. Those pages did not establish a current CCRI-specific blueprint. This guide deliberately follows the evidenced ACRP investigator credential lineage and current CPI examination; it does not equate the separate programs.
Global Certification in Pharmacy — Pharma Research · The Society of Clinical Research Professional — SCRP · CPI Certification — ACRP
This guide follows the Academy of Clinical Research Professionals' current Certified Principal Investigator pathway. It addresses investigator competence rather than a professional license or specialty qualification. The historical ACRP CCRI designation belongs to the documented lineage leading to CPI. These independently authored materials are educational practice and are not official examination questions.
Outline used: 2024 CPI Examination Content Outline currently linked by ACRP, checked on 2026-10-12; the outline does not state a separate effective date. ACRP examinations adopted ICH E6(R3) on 2026-07-15. Historical mapping: an ACRP-hosted 2012 account identifies Certified Clinical Research Investigator (CCRI) as an earlier ACRP investigator designation consolidated into Certified Physician Investigator (CPI); a historical APPI guide corroborates integration of the investigator programs in 2006. ACRP's February 2015 publication documents the subsequent change from Certified Physician Investigator to Certified Principal Investigator. The assigned CCRI slug is preserved for this evidenced historical mapping, not presented as a separate current ACRP examination.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Scientific Rationale and Principles of Research Design15/100 allocation (15%)
1.How does a study objective determine its primary endpoint?
A study objective states the clinical question, while the endpoint specifies the outcome used to answer it, including measurement and assessment timing. The primary endpoint should represent the principal objective and support the planned analysis and sample size. A convenient measurement is not automatically a clinically meaningful endpoint. Investigators should distinguish direct clinical outcomes from surrogate measures and understand what evidence connects a proposed surrogate to participant benefit.
Apply it
A trial seeks to reduce disabling exacerbations but proposes attendance at education sessions as its primary endpoint. Ask how attendance answers the clinical objective and whether an exacerbation outcome better measures the intended benefit.
Common pitfall: Choosing an easily collected endpoint can improve completeness while weakening relevance. Operational convenience does not establish that a measurement represents the intended clinical benefit.
ICH E8(R1) — General Considerations for Clinical Studies · ICH E9 — Statistical Principles for Clinical Trials
2.Why must randomization and allocation concealment work together?
Randomization uses a chance mechanism to assign treatments, reducing systematic allocation differences and supporting statistical inference. Allocation concealment prevents those enrolling participants from knowing the next assignment before eligibility and enrollment are settled. A genuinely random sequence can still produce selection bias if staff can predict assignments. The discriminating question is whether knowledge of the upcoming treatment could influence who enters the trial or when enrollment occurs.
Apply it
A coordinator can view tomorrow's treatment assignments and delays enrolling a frail candidate until the preferred treatment appears. The random sequence remains intact, but concealment has failed and enrollment decisions can now introduce bias.
Common pitfall: Calling a trial randomized does not prove assignments were concealed. Alternating treatments or using an accessible assignment list permits prediction and undermines unbiased enrollment.
3.How does blinding reduce bias after treatment assignment?
Blinding limits knowledge of assigned treatment among participants, care providers, assessors or analysts when that knowledge could influence behavior or evaluation. It addresses biases that occur after assignment, whereas concealment protects the enrollment decision. When treatment blinding is impractical, blinded endpoint assessment and standardized procedures may still reduce bias. Investigators should identify who knows the assignment and which decisions or measurements that knowledge could affect.
Apply it
A device trial cannot hide the procedure from the operating clinician. The site instead arranges independent assessors who do not know treatment assignment and use predefined criteria to evaluate the primary functional outcome.
Common pitfall: An open-label design does not eliminate every opportunity to control bias. Conversely, describing a study as blinded is insufficient without identifying the blinded roles.
4.Which assumptions determine statistical power and sample size?
Power is the probability of rejecting the null hypothesis when a specified alternative is true. Sample size depends on the target effect, variability or event rate, significance level, desired power and design features. Smaller target differences or greater variability usually require more participants. Anticipated attrition also matters. Investigators should assess whether assumptions are plausible for their population rather than interpreting the planned enrollment number as self-justifying evidence.
Apply it
A site expects substantially fewer outcome events than the protocol assumed. Raise the discrepancy during feasibility review because fewer events can reduce information and power even when the planned number of participants is enrolled.
Common pitfall: More participants cannot repair an irrelevant endpoint or systematic bias. Power concerns random uncertainty under stated assumptions, not the overall validity of every study decision.
5.How should confidence intervals and p-values inform interpretation?
A p-value describes how incompatible the observed data are with a specified null model; it is not the probability that the null hypothesis is true. A confidence interval expresses estimation uncertainty under the analysis assumptions and shows effect sizes compatible with the data. Interpretation should consider clinical importance, precision and design quality together. Statistical significance alone does not establish a meaningful benefit, and nonsignificance does not establish equivalence.
Apply it
A treatment difference is statistically significant, but its confidence interval lies entirely within effects considered clinically trivial. Explain that the study supports a small difference while leaving the claim of meaningful participant benefit unsupported.
Common pitfall: A narrow confidence interval can precisely estimate a clinically unimportant effect. A wide interval crossing no effect can leave important benefit and harm unresolved.
6.What establishes noninferiority rather than a failed superiority result?
A noninferiority trial asks whether the experimental treatment is worse than the comparator by less than a prespecified, justified margin. The relevant confidence bound must exclude unacceptable loss of efficacy in the chosen effect direction. The comparator must have credible effectiveness in the trial setting. Failure to show superiority does not answer this question. Protocol adherence and analysis choices require particular care because dilution of treatment differences can falsely favor noninferiority.
Apply it
Higher response is better, the experimental-minus-control difference is minus two percentage points, and its confidence interval is minus seven to three. With a minus five-point noninferiority boundary, noninferiority is not established because the interval includes unacceptable loss.
Common pitfall: Similar observed response rates do not establish noninferiority. A margin chosen after seeing results cannot provide the same protection as a justified prespecified margin.
7.How does an estimand clarify the treatment effect of interest?
An estimand specifies the treatment effect being estimated through the treatment conditions, population, outcome variable, handling of intercurrent events and population-level summary. These attributes align the clinical question with data collection and analysis. For example, treatment discontinuation can be handled differently depending on whether interest concerns assignment to treatment or outcomes under continued treatment. Investigators need this distinction to understand which observations remain necessary after treatment changes.
Apply it
A protocol asks about outcomes after assignment regardless of rescue medication. When a participant starts rescue therapy, continue collecting the scheduled outcome as specified; excluding that observation would change the treatment question being answered.
Common pitfall: An estimand is not merely the statistical model. Choosing an analysis without specifying the clinical question can conceal incompatible assumptions about treatment changes.
8.Why are intercurrent events different from missing data?
An intercurrent event occurs after treatment initiation and affects interpretation or existence of the outcome, such as rescue treatment or treatment discontinuation. Missing data arise when a measurement required for the chosen estimand is unavailable. An event can occur without causing missing data if follow-up continues. The distinction determines whether the response is to apply the prespecified event strategy, recover an observation, or assess assumptions about unavailable information.
Apply it
A participant stops study medication but attends the outcome visit. Discontinuation is an intercurrent event; the recorded outcome is not missing. Apply the protocol's estimand strategy rather than automatically deleting the participant's observed measurement.
Common pitfall: Treating every discontinuation as missing data confuses treatment exposure with observation availability. Conversely, recording the reason for discontinuation does not replace an unavailable outcome.
9.When do multiple analyses threaten a confirmatory conclusion?
Testing multiple endpoints, treatment comparisons or repeated interim analyses creates additional opportunities for a false positive conclusion. A confirmatory strategy should prespecify which claims are intended and how the overall type I error is controlled. Exploratory findings can generate hypotheses but need appropriate qualification. Investigators should recognize that selecting the smallest p-value after examining many results changes the evidential meaning of an apparently significant individual test.
Apply it
A study misses its primary endpoint but finds one favorable result among twenty exploratory measures. Describe that finding as exploratory and examine the planned testing strategy before presenting it as confirmatory evidence of treatment efficacy.
Common pitfall: A nominally significant subgroup result does not automatically rescue a failed primary analysis. Prespecification and multiplicity control determine which confirmatory claims the design supports.
Ethical and Safety Considerations22/100 allocation (22%)
10.How should investigators judge whether trial risks remain justified?
Ethical acceptability depends on the importance of the research objective, scientific validity, anticipated benefits and foreseeable risks and burdens. Risk assessment continues throughout the trial as new information emerges. Investigators should distinguish potential benefit to participants from the social value of knowledge and should reduce avoidable risk. A favorable initial assessment does not justify continuing unchanged when accumulating evidence materially alters the balance for the enrolled population.
Apply it
Several participants develop a previously unrecognized complication with little prospect of direct benefit. Provide appropriate care, communicate the information through required channels and reassess whether enrollment or treatment should continue under the existing safeguards.
Common pitfall: Prior ethics approval is not permanent proof of acceptable risk. New information can require additional safeguards, revised consent, a study change or termination.
WMA Declaration of Helsinki — Ethical Principles for Medical Research Involving Human Participants
11.What makes informed consent a valid decision process?
Valid consent requires understandable information, an opportunity to ask questions, sufficient time for consideration and a voluntary decision by a person able to consent or an appropriate legally acceptable representative. Required documentation records that process but does not replace it. Investigators should explain research purpose, procedures, risks, alternatives and withdrawal rights without promising benefit. A useful discriminating cue is whether the participant understands how research differs from individualized clinical care.
Apply it
A candidate signs quickly but says the investigator will choose whichever study arm is best personally. Pause enrollment, explain random assignment and alternatives, and reassess understanding before treating the signature as evidence of informed agreement.
Common pitfall: A signed form cannot cure a material misunderstanding. Repeating technical language without checking comprehension may document disclosure while leaving the actual decision inadequately informed.
12.When does new information require renewed consent discussions?
Consent continues throughout participation. Information that may affect willingness to remain in a trial should be communicated promptly, and revised consent materials should receive required approval before routine use. The response depends on the significance of the information and applicable requirements; a new signature alone is not the objective. Investigators should explain what changed, how it affects the participant's choices and what alternatives or protective actions are available.
Apply it
A new safety finding increases a risk relevant to participants already receiving treatment. Arrange the required communication and consent updates, explain the changed risk individually, and document each participant's informed decision about continuing in the trial.
Common pitfall: Waiting until the next annual review can leave participants making decisions with outdated information. Administrative scheduling should not determine when material new risks are discussed.
13.How can a dependent relationship undermine voluntary consent?
A participant may feel pressure when the person seeking consent controls clinical care, employment, grades or another valued relationship. Under Helsinki paragraph 27, when a potential participant is in a dependent relationship with the researcher or may consent under duress, informed consent must be sought by an appropriately qualified person independent of that relationship. Reassurance that refusal will not affect ordinary care, employment or other interests provides additional protection; it does not replace the independent-person requirement.
Apply it
A department head proposes recruiting junior employees into a trial they lead. Arrange consent through an appropriately qualified person independent of the employment relationship, and clearly protect employees' ability to decline without consequences for their professional standing.
Common pitfall: A voluntary-participation statement or reassurance from the authority figure does not substitute for independent consent-taking when dependency or duress threatens voluntariness.
WMA Declaration of Helsinki — Ethical Principles for Medical Research Involving Human Participants
14.Which safeguards make inclusion of vulnerable participants defensible?
Under Helsinki paragraph 20, research involving individuals, groups or communities in situations of particular vulnerability must respond to their health needs and priorities, and they must stand to benefit from the resulting knowledge, practices or interventions. Inclusion is justified only when the research cannot be carried out in a less vulnerable group or community, or when exclusion would perpetuate or exacerbate disparities. Tailored safeguards remain necessary. Under paragraph 28, research involving people incapable of consenting additionally requires likely personal benefit or only minimal risk and minimal burden, together with legally authorized representative consent and other applicable protections.
Apply it
For a study involving adults with cognitive impairment, establish responsiveness to their health needs, anticipated benefit to the group, and why a less vulnerable population cannot answer the question or exclusion would worsen disparities. For each participant incapable of consenting, also establish likely personal benefit or only minimal risk and minimal burden, obtain representative consent and provide tailored safeguards.
Common pitfall: Scientific interest, representative permission and extra monitoring do not alone justify inclusion. Group-level benefit does not replace the additional personal-benefit or minimal-risk-and-minimal-burden condition for people incapable of consenting.
WMA Declaration of Helsinki — Ethical Principles for Medical Research Involving Human Participants · ICH E6(R3) Guideline for Good Clinical Practice
15.How should assent and a child's refusal affect pediatric participation?
Parental or representative permission does not eliminate the need to involve a child according to maturity and psychological development. Information and assent procedures should be age appropriate. The E11(R1) addendum instructs respect for refusal to assent or withdrawal of assent. The original E11 section 2.6.3 describes a narrow circumstance in therapeutic studies for serious or life-threatening diseases: the investigator and parent or legal guardian judge that failing to participate would jeopardize the child's welfare, and continued parental or guardian consent may permit participation. This specific circumstance must be distinguished from the addendum's instruction; potential therapeutic benefit alone does not justify overriding dissent.
Apply it
An adolescent understands a study involving optional research biopsies and clearly refuses them despite parental enthusiasm. Respect the refusal and determine participation consequences under the protocol; parental permission alone does not justify overriding the adolescent's expressed objection.
Common pitfall: Assent is not a miniature adult consent form or a procedural signature. Do not turn the original serious-disease welfare circumstance into a general permission to override refusal whenever research offers possible benefit.
ICH E11(R1) — Clinical Investigation of Medicinal Products in the Pediatric Population
16.Which outcomes make an adverse event serious?
Seriousness is determined by outcomes or medical significance: death, a life-threatening event, inpatient hospitalization or its prolongation, persistent or significant disability or incapacity, congenital anomaly, or another medically important event. Medical judgment can identify events requiring intervention to prevent such outcomes. Under E2A, life-threatening means the participant was at risk of death when the event occurred, rather than that a more severe version might have been fatal.
Apply it
A participant develops an acute reaction requiring urgent intervention to prevent respiratory failure but avoids admission. Evaluate it as potentially medically important and serious; absence of hospitalization does not by itself exclude the serious-event classification.
Common pitfall: Hospital admission is one seriousness criterion, not the entire definition. An event can be serious through medical importance even when prompt treatment prevents admission.
ICH E2A — Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
17.Why are severity and seriousness assessed separately?
Severity describes intensity, such as mild, moderate or severe, using the applicable assessment method. Seriousness concerns defined outcomes or medical significance. A severe symptom can remain nonserious, while a relatively mild symptom can accompany an event meeting a seriousness criterion. Both assessments should be documented because they answer different questions. Investigators should not infer reporting obligations from an intensity grade without evaluating seriousness, causality and relevant reporting requirements.
Apply it
A participant reports a severe headache managed at home without concerning findings or functional consequences meeting seriousness criteria. Record its intensity accurately, assess the clinical situation, and determine seriousness separately rather than labeling it serious solely because it is severe.
Common pitfall: The everyday meaning of serious can blur two distinct classifications. An intensity grading scale does not replace assessment against serious adverse-event criteria.
ICH E2A — Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
18.How should an investigator assess whether an event is treatment related?
Causality assessment considers whether there is a reasonable possibility that the investigational product caused the event. Relevant evidence includes timing, pharmacology, alternative explanations and changes after stopping or restarting treatment when such information exists. An adverse event does not require a causal relationship, whereas an adverse drug reaction does. Investigators should record a reasoned assessment using the required method and update it when meaningful follow-up information changes the judgment.
Apply it
A participant develops a rash after starting study treatment while also receiving an antibiotic. Evaluate both exposures, timing, clinical pattern and other causes. Document the uncertainty and rationale rather than declaring study-treatment causality from chronology alone.
Common pitfall: An event occurring after dosing is not automatically a reaction. Conversely, a plausible alternative cause does not necessarily eliminate a reasonable possibility of treatment involvement.
ICH E2A — Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
19.What makes an adverse reaction unexpected?
Expectedness concerns consistency with the applicable product information, including the reaction's nature or severity. A reaction can be unexpected when a related symptom is listed but the observed manifestation is materially different or more severe than described. Expectedness is separate from causality and seriousness. Investigators should provide accurate clinical details so the sponsor can assess the event against the appropriate reference information and determine applicable expedited reporting obligations.
Apply it
Reference information describes transient mild liver-enzyme elevations, but a participant develops treatment-related hepatic failure. The listed laboratory abnormality does not automatically make hepatic failure expected; compare the actual reaction's nature and severity with the reference description.
Common pitfall: Finding a broad organ-system term in product information does not settle expectedness. The actual clinical reaction must match sufficiently in nature and severity.
ICH E2A — Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
20.How do immediate investigator SAE notification and sponsor expedited reporting differ?
Under E6(R3) section 2.7.2(b), investigators must report serious adverse events to the sponsor immediately after reasonably becoming aware of them, including a causality assessment. Exceptions are limited to SAEs identified in the protocol as not requiring immediate reporting, consistent with applicable requirements. Provide follow-up information without awaiting diagnostic certainty. Sponsor expedited reporting is a separate decision: a suspected unexpected serious adverse reaction, or SUSAR, combines suspected causality, unexpectedness and seriousness. In E2A's clinical-investigation setting, fatal or life-threatening unexpected reactions require sponsor notification to regulators as soon as possible and within seven calendar days of sponsor knowledge that the case qualifies, followed by as complete a report as possible within eight additional calendar days. Other serious unexpected reactions require reporting as soon as possible and within fifteen calendar days after qualifying minimum information is known. These are guideline standards; applicable local requirements must also be followed.
Apply it
An inpatient admission after an apparently unrelated accident requires immediate investigator-to-sponsor SAE reporting unless a permitted protocol exception applies, even though it is not a SUSAR. Unexpected hepatic failure with suspected treatment causality also requires immediate site notification. If it was life-threatening when it occurred, the sponsor's E2A expedited pathway uses seven calendar days plus eight additional days for a fuller report; if serious but neither fatal nor life-threatening, the fifteen-day pathway applies.
Common pitfall: The sponsor's seven- or fifteen-day clock is not the investigator's notification deadline. An uncertain final diagnosis does not justify delaying the immediate SAE report and initial causality assessment.
ICH E6(R3) Guideline for Good Clinical Practice · ICH E2A — Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
21.How should clinically important laboratory alerts be managed?
A laboratory alert requires timely qualified review, assessment of participant risk and action consistent with clinical needs and protocol requirements. The investigator should evaluate the result in context, arrange appropriate confirmation or care, and document decisions and follow-up. A result's presence in an electronic system is not evidence that anyone acted on it. Reporting an abnormality also does not replace the medical assessment needed to protect the participant.
Apply it
A central laboratory flags a potentially dangerous electrolyte result after clinic hours. Activate the site's coverage process, obtain qualified assessment and contact the participant as appropriate; do not leave the alert for routine data entry the next day.
Common pitfall: Automatically filing laboratory reports can create an appearance of completeness while urgent findings remain unreviewed. Receipt, clinical review and documented action are separate steps.
22.How does stopping treatment differ from withdrawing all participation?
Stopping investigational treatment, declining a procedure and withdrawing from further trial participation are different decisions. Investigators should clarify the participant's wishes without pressure, explain medically relevant follow-up and respect the resulting limits. Continued outcome or safety collection may remain possible if the participant agrees. Reasons for discontinuation should be sought respectfully, but participants need not justify withdrawal. Existing data handling follows consent, applicable requirements and the study's documented arrangements.
Apply it
A participant wants to stop tablets because of nausea but is willing to attend follow-up visits. Clarify and document that choice, arrange clinical review, and continue only the procedures and data collection that remain authorized.
Common pitfall: Treating every treatment stop as complete withdrawal can unnecessarily lose safety and outcome information. Continued contact must still respect the participant's expressed choices.
ICH E6(R3) Guideline for Good Clinical Practice · ICH E9(R1) — Addendum on Estimands and Sensitivity Analysis
Product Development and Regulation12/100 allocation (12%)
23.How do development objectives differ across clinical studies?
Clinical development builds evidence through studies addressing human pharmacology, exploratory therapeutic questions, confirmatory questions and therapeutic use. These objectives often align with familiar development phases, but phases can overlap and do not define every study's purpose. The objective determines suitable participants, endpoints, controls and risk management. Investigators should identify the actual question and existing evidence rather than assume that a phase label alone specifies design or expected benefit.
Apply it
A development program proposes a small study to refine a dose range before a large efficacy trial. Evaluate dose-response and safety learning as its principal purpose rather than expecting it to provide definitive confirmation of clinical benefit.
Common pitfall: Phase labels are useful shorthand but do not replace study objectives. A large enrollment count alone does not make a study confirmatory in purpose.
24.Why must the Investigator's Brochure be interpreted as evolving evidence?
The Investigator's Brochure brings together relevant nonclinical and clinical information needed to understand the rationale and support appropriate study conduct. Investigators should use it to interpret foreseeable risks, precautions and emerging findings alongside the protocol and current safety communications. It requires review and updating as relevant knowledge develops. A brochure is neither a guarantee of safety nor a substitute for participant-specific medical judgment and timely consideration of new information.
Apply it
An updated brochure identifies a newly recognized interaction relevant to an enrolled participant's concomitant medication. Review the participant's situation, apply required precautions, and assess whether communication, consent changes or protocol-related action is needed before the next exposure.
Common pitfall: Keeping an updated brochure in the file does not demonstrate that its implications were reviewed. New evidence must reach staff making affected participant-care decisions.
25.What does independent ethics approval authorize?
An IRB or IEC independently reviews the ethical acceptability of proposed research, including participant protection and consent arrangements. Favorable opinion or approval is required before the relevant study activities begin, together with any other necessary authorizations. Its independence does not transfer medical responsibility away from the investigator. Investigators must know which documents and versions are approved and which later changes or information require submission under the applicable review process.
Apply it
The sponsor approves a recruitment advertisement, but the site's ethics body has not reviewed it where review is required. Obtain the necessary ethics approval before using the advertisement; sponsor acceptance alone does not authorize its local use.
Common pitfall: Sponsor approval and ethics approval serve different functions. Neither should be treated as automatic evidence that every site document or later change is authorized.
26.When may a protocol amendment be implemented?
A planned substantive protocol change normally requires sponsor agreement and required ethics or regulatory review before implementation. Changes needed to eliminate an immediate hazard are treated differently and require prompt subsequent documentation and communication. Administrative or logistical changes may have different review requirements. Investigators should distinguish a proposed scientific or procedural change from routine clarification and maintain control of effective versions, staff training and participant information affected by the amendment.
Apply it
A sponsor sends a revised schedule adding an invasive procedure and asks the site to begin tomorrow. Confirm required approvals and implementation readiness first, then train staff and address consent implications before performing the new procedure.
Common pitfall: A sponsor email is not a substitute for required amendment approval. Classifying a substantive procedural change as administrative can bypass essential independent review.
27.How does an independent data monitoring committee protect trial decisions?
An independent data monitoring committee can review accumulating safety and efficacy information, including unblinded comparative data when appropriate, and recommend continuation, modification or termination under its charter. This structure supports participant protection while limiting unnecessary disclosure to the operational study team. Its recommendations do not eliminate sponsor or investigator responsibilities. The key distinction is between independent aggregate trial assessment and the investigator's continuing obligation to assess and care for individual participants.
Apply it
A blinded investigator wants comparative interim results to decide whether recruitment should continue. Follow the established monitoring structure rather than requesting unrestricted unblinded data; continue assessing local safety and provide relevant observations to the designated review process.
Common pitfall: A monitoring committee does not replace local clinical judgment or routine safety reporting. Independent aggregate review and immediate participant care address different levels of responsibility.
ICH E6(R3) Guideline for Good Clinical Practice · ICH E9 — Statistical Principles for Clinical Trials
28.How do monitoring, auditing and inspection differ?
Monitoring oversees trial progress and compliance as part of trial management. An audit is a systematic independent examination of trial activities and records, distinct from routine monitoring. An inspection is an official review by a regulatory authority. Each can examine participant protection and data reliability, but their authority and organizational roles differ. Investigators should provide authorized access and accurate explanations without altering original records to make findings appear less significant.
Apply it
A regulatory authority requests source records during a site inspection. Arrange authorized access and knowledgeable staff, preserve the records and answer accurately. A recent favorable monitoring report does not remove the authority's ability to inspect the same activities.
Common pitfall: A monitoring visit is not an independent audit or regulatory inspection. Similar document requests do not make the purpose, authority or independence of these activities identical.
29.What must happen when a trial is suspended or terminated early?
Early suspension or termination requires attention to participant welfare, appropriate therapy and follow-up, and timely communication to the relevant parties under applicable requirements. The reason matters because a safety concern may require different immediate action from an administrative closure. Investigators should preserve records and clarify responsibilities with the sponsor. Ending recruitment or treatment does not erase obligations to explain the situation, manage ongoing clinical needs and complete required reporting.
Apply it
A sponsor ends a study for commercial reasons while participants remain on treatment. Inform participants appropriately, arrange treatment transitions and necessary follow-up, and complete required notifications rather than treating the closure notice as the end of all responsibilities.
Common pitfall: Administrative termination does not justify abrupt abandonment of participant care. Study closure and medically appropriate transition planning must be managed as connected but distinct tasks.
Clinical Trial Operations21/100 allocation (21%)
30.How should a protocol be tested for operational feasibility?
Protocol feasibility asks whether required procedures, timing, eligibility decisions and follow-up can be performed reliably in the proposed setting. Investigators should examine dependencies such as laboratory turnaround, specialist availability and treatment windows, not just whether individual services exist. A scientifically sound design can still fail operationally. The decisive issue is whether the complete sequence can work for real participants without predictable deviations or compromising safety and data quality.
Apply it
Eligibility requires a central result before dosing within a narrow window, but routine laboratory turnaround exceeds that window. Resolve the timing conflict with the sponsor before activation rather than assuming staff can compensate after enrollment begins.
Common pitfall: A service listed in a hospital directory is not proof of feasible trial delivery. Availability, turnaround, scheduling and protocol-specific capability must align together.
31.How can recruitment estimates avoid systematic overstatement?
A credible recruitment estimate starts with the accessible population and progressively applies eligibility, willingness, competing-study and logistical constraints. Historical diagnoses alone overstate enrollment potential because many patients will fail criteria or decline participation. Investigators should distinguish referrals, screened candidates and enrolled participants. Evidence from comparable studies and realistic screening pathways is more useful than an optimistic total that ignores the participant burden and the site's actual recruitment access.
Apply it
A clinic has 200 potentially relevant patients, half meet key criteria, and about one quarter of those are likely to consent. A preliminary estimate is 25 participants before considering competition, visit burden and screening failures from remaining criteria.
Common pitfall: Counting every patient with the target diagnosis confuses disease prevalence with recruitable participants. Each exclusion, access barrier and competing commitment can materially shrink the pool.
32.What responsibility remains after an investigator delegates a task?
An investigator may delegate appropriate trial activities to qualified individuals, but retains responsibility for oversight of those activities. Delegation should fit the person's education, training, experience and applicable professional requirements. Oversight should reflect the activity's importance and risk, including review of problems and performance. A delegation record identifies assignments; it does not prove competence, adequate supervision or completion of the work, and it does not transfer the investigator's accountability.
Apply it
A trained coordinator enters laboratory data, but the investigator never reviews clinically important alerts. Delegating entry is reasonable; failing to ensure qualified medical review is not. Establish oversight that separates administrative processing from participant-care decisions.
Common pitfall: A signed delegation log cannot compensate for insufficient qualifications or absent supervision. Accountability follows the investigator even when another person performs the assigned activity.
33.How should training demonstrate readiness for assigned work?
Training should prepare staff for their actual trial responsibilities, including protocol-specific procedures, safety pathways and relevant systems. Attendance records show participation but may not establish ability to perform a complex task. Investigators should use appropriate demonstrations, supervised practice or review when needed and update training after relevant changes. The discriminating question is whether the staff member can execute the assigned activity correctly under the conditions expected during the trial.
Apply it
A new coordinator completes general GCP training but has never used the trial's emergency reporting workflow. Before independent coverage, review the protocol-specific process and confirm that the coordinator can identify contacts, required information and escalation steps.
Common pitfall: General certification or a training certificate does not establish competence in every study procedure. Training must address the activity and the current protocol version.
34.Which resources must be secured before accepting a study?
Investigators need adequate time, qualified staff, suitable facilities and access to the resources required for safe and reliable conduct throughout the expected study period. Resource assessment should include peaks in workload, absence coverage and follow-up obligations, rather than only startup capacity. Competing trials can consume the same resources. Acceptance is defensible when the site can meet the complete protocol and oversight burden without relying on unsupported assumptions about future staffing.
Apply it
A site can perform screening visits but has no qualified coverage during the investigator's planned extended absence. Establish an appropriate coverage arrangement and confirm capacity for ongoing care before committing to enrollment during that period.
Common pitfall: Startup readiness is not sustained capacity. A site may have sufficient rooms and equipment yet lack the qualified time needed for continuing clinical oversight.
35.How should a protocol deviation be evaluated and documented?
A deviation is a departure from the approved protocol or required study procedures. Evaluation should consider participant safety, rights and data reliability, then determine corrective action and required communication. Documentation should describe what happened, why, its consequences and the response without disguising the departure. Repeated deviations may reveal an underlying system problem. A deviation record does not itself authorize future departures or substitute for an amendment when the planned conduct needs changing.
Apply it
A participant's assessment occurs outside the allowed visit window. Record the actual date and reason, assess effects on safety and endpoint interpretation, and follow reporting requirements. Investigate scheduling patterns if similar deviations are recurring across participants.
Common pitfall: Changing the recorded date to fit the window converts a documented deviation into unreliable data. Transparency is necessary even when the clinical consequences appear minor.
36.When can immediate participant protection precede protocol approval?
An investigator may depart from the protocol when necessary to eliminate an immediate hazard to a participant. This exception addresses urgent protection, not convenience or a preferred clinical schedule. The investigator should document the event, rationale and actions and communicate promptly through the required sponsor, ethics and regulatory pathways. Any continuing procedural change must then follow the applicable approval process rather than relying indefinitely on the emergency exception.
Apply it
A participant develops an acute condition making the next protocol procedure unsafe. Withhold the hazardous procedure and provide necessary care, then document and report the departure. Do not wait for an amendment before removing the immediate danger.
Common pitfall: Routine scheduling pressure is not an immediate hazard. The emergency exception cannot be used as standing permission to bypass approval for planned procedural changes.
37.How does effective CAPA address causes rather than symptoms?
Corrective and preventive action starts with understanding the problem's significance and underlying causes. Correction addresses the immediate instance; corrective action reduces recurrence from the identified cause; preventive action addresses potential problems where appropriate. A useful plan assigns responsibility, completion criteria and an effectiveness check. Retraining can help when knowledge is deficient, but repeated human-error labels often conceal poor workflows, inaccessible instructions, workload problems or inadequate system controls.
Apply it
Several samples miss processing deadlines because courier collection occurs before the last clinic visit. Correct the affected records, redesign collection or transport timing, assign an owner and check subsequent deadline performance instead of simply asking staff to be more careful.
Common pitfall: Completing a training attendance sheet is not an effectiveness check. The relevant evidence is whether the revised process actually prevents the identified failure from recurring.
38.How should quality management be proportional to trial risk?
Quality management should focus effort on factors critical to participant protection and reliable results. The intensity of controls should reflect the likelihood, detectability and consequences of errors rather than applying identical scrutiny to every field. Quality by design seeks to prevent important problems through feasible procedures and clear responsibilities. Investigators should identify which failures could change eligibility, treatment, safety decisions or primary outcomes and ensure those processes receive appropriate attention.
Apply it
A site is choosing between extra review of decorative report formatting and verification of eligibility laboratory values. Prioritize the eligibility process because an error could expose an unsuitable participant to treatment and compromise the study population.
Common pitfall: Proportionality does not permit ignoring inconvenient obligations. It directs effort toward important risks while maintaining required controls and a reasoned basis for the approach.
ICH E8(R1) — General Considerations for Clinical Studies · ICH E6(R3) Guideline for Good Clinical Practice
39.How should authorized source-data access support monitoring?
Monitoring requires access to relevant records through arrangements that permit verification while protecting confidentiality. Investigators should ensure that authorized monitors can review the needed information using appropriate access controls and participant disclosures. Access should be sufficient for the purpose without exposing unrelated records unnecessarily. A site should resolve technical or institutional barriers before they prevent meaningful oversight; simply stating that data are in a hospital system does not make them verifiable.
Apply it
A monitor can see transcribed study worksheets but cannot review the hospital reports supporting eligibility. Arrange authorized access or another acceptable verification pathway that preserves confidentiality and permits the relevant source information to be assessed.
Common pitfall: Confidentiality is not a reason to make authorized verification impossible. Conversely, facilitating review does not justify sharing unrestricted credentials or unrelated participant records.
40.What changes when an investigator also acts as sponsor?
A sponsor-investigator undertakes responsibilities associated with both initiating or managing the trial and conducting it. Investigator responsibilities do not absorb or replace sponsor duties such as appropriate trial oversight and quality arrangements. The exact activities depend on the study, but the combined role requires deliberate identification of both responsibility sets. Institutional support or outsourced services can help perform activities without making the combined accountability disappear.
Apply it
An academic investigator initiates a trial and assumes ordinary site monitoring by a commercial sponsor will occur. Map the sponsor responsibilities explicitly, establish suitable monitoring and safety arrangements, and document who will perform each required activity.
Common pitfall: An investigator-initiated label does not create an exemption from sponsor responsibilities. Academic purpose and limited funding do not remove the need for appropriate oversight.
41.How should service providers be qualified and overseen?
A service provider should be suitable for the delegated activity, with responsibilities, interfaces and access to relevant information clearly defined. Qualification should assess capability for the actual trial requirements, not merely reputation or a general certificate. Oversight should reflect the activity's importance and include handling of failures and changes. Investigators remain responsible for appropriate oversight of activities they delegate, including services that affect participant safety or the reliability of study assessments.
Apply it
A site selects a local laboratory for a time-sensitive endpoint assay. Confirm the required method, sample handling, turnaround, reporting and quality arrangements before use, then monitor performance against those requirements during participant follow-up.
Common pitfall: A vendor's general accreditation does not prove suitability for every trial-specific task. Defined deliverables and continuing performance information remain necessary for meaningful oversight.
42.How should study results be communicated responsibly?
Responsible communication explains findings in a form suited to the audience while preserving their limitations. Investigators should distinguish the study's prespecified conclusions from exploratory observations and explain uncertainty without exaggerating individual benefit. Participants should receive appropriate information about trial outcomes in line with consent arrangements and applicable requirements. Publication and reporting responsibilities also support the social value of participation by making results available rather than selectively emphasizing favorable findings.
Apply it
Participants ask whether a favorable average result means their own health improved because of treatment. Explain the group-level finding, uncertainty and limits of individual inference, and provide the appropriate participant-facing results information when available.
Common pitfall: A statistically favorable average does not prove benefit for every participant. Selective communication of positive outcomes can misrepresent the evidence and undermine informed interpretation.
WMA Declaration of Helsinki — Ethical Principles for Medical Research Involving Human Participants · ICH E9 — Statistical Principles for Clinical Trials
Study and Site Management17/100 allocation (17%)
43.How should investigational product accountability be reconciled?
Product accountability links receipt, stock, dispensing, participant returns and final disposition so that movements can be traced and discrepancies investigated. Reconciliation requires clear categories: usable stock, dispensed units and returned units are not interchangeable. Records should identify relevant quantities, dates and product identifiers. A balanced total supports traceability but does not alone prove correct administration. Investigators should resolve unexplained differences rather than adjusting records merely to force agreement.
Apply it
A site receives 120 units, dispenses 48 and returns 12 unused units from site stock to the sponsor. Expected remaining site stock is 60 units. Participant returns, if any, must be tracked separately according to their disposition.
Common pitfall: Adding participant-returned units directly to usable stock can conceal both accountability and suitability problems. Physical possession does not mean a unit is available for redispensing.
44.What should happen after a product storage excursion?
Investigational products should be stored under specified conditions with controls capable of detecting relevant excursions. When conditions fall outside limits, affected stock should be identified and prevented from use until an authorized assessment determines suitability. Returning the environment to normal does not establish that the product remained acceptable. Document the excursion's duration and magnitude, notify the appropriate party and preserve the decision and resulting disposition in the accountability records.
Apply it
A refrigerator is found above its permitted range after a weekend. Segregate affected product, preserve temperature information and seek the required stability assessment. Resume dispensing only after the authorized decision supports use of the affected stock.
Common pitfall: A normal current temperature does not erase prior exposure. Visual appearance also cannot establish product stability after an excursion outside specified storage conditions.
45.How should dispensing preserve assignment and blinding controls?
Dispensing must follow the protocol's treatment assignment, product identification and authorization procedures. Verification should connect the correct participant, visit and assigned product without unnecessary disclosure of treatment identity. Staff should understand permitted substitutions and the route for resolving discrepancies. A locally convenient substitution can compromise both safety and the randomized comparison. When assignment information conflicts with available stock, the site should resolve the issue through the designated process before dispensing.
Apply it
The assigned kit is unavailable, but another kit appears physically identical. Do not substitute based on appearance. Contact the designated supply or randomization support process and document the authorized resolution before providing investigational product to the participant.
Common pitfall: Identical packaging does not establish interchangeable assignment. Bypassing the allocation system can create a treatment error even when the product label looks familiar.
46.How should participant product use be taught and assessed?
Participants need clear instructions for product use, storage, restrictions and responses to missed or uncertain use as specified by the study. Understanding should be checked rather than assumed from a handout. Adherence assessment combines appropriate information such as discussion, diaries and accountability records while recognizing each method's limits. Investigators should explore barriers without blame because inaccurate reassurance can conceal exposure differences, safety risks and problems interpreting treatment outcomes.
Apply it
Returned tablets suggest expected use, but a participant reports discarding doses after nausea. Record the actual account, arrange clinical review and reinforce protocol-specific instructions. Do not treat the pill count as stronger evidence than the newly disclosed behavior.
Common pitfall: Pill counts measure units returned, not ingestion. Punitive questioning can encourage concealment and make adherence information less reliable when accurate exposure history matters most.
47.Why must equipment suitability extend beyond a calibration sticker?
Equipment must be suitable for its intended trial use and maintained or calibrated as appropriate. A current sticker is useful evidence but does not establish correct settings, operator technique, measurement range or compatibility with the protocol. Failures can affect safety decisions and endpoint comparability. Investigators should ensure qualified use, relevant records and a response process for malfunctions, including assessment of measurements obtained since the equipment was last known to function properly.
Apply it
A scale passes routine calibration, but staff weigh participants with inconsistent clothing and different accessories despite a standardized endpoint procedure. Correct the measurement process and assess affected data; equipment calibration alone cannot remove procedural variation.
Common pitfall: Technically functioning equipment can still produce unsuitable trial measurements. The device, operating conditions, user technique and protocol method must all support the intended measurement.
48.How should specimen workflows protect validity and staff safety?
A specimen workflow must preserve correct identification, required collection and processing conditions, traceable transfer and suitable storage or shipment. Biological and other hazardous materials also require appropriate handling safeguards. The critical conditions depend on the analysis; an intact container can still hold an invalid sample if timing or temperature requirements were missed. Investigators should ensure staff know the complete pathway and can identify failures before unreliable results enter clinical or endpoint decisions.
Apply it
A sample reaches the laboratory correctly labeled but was processed after the protocol's maximum interval. Record the departure, ask whether the sample remains analytically suitable and arrange appropriate action rather than assuming successful delivery establishes valid handling.
Common pitfall: A courier receipt proves transfer, not sample validity. Identification, timing, environmental conditions and safe handling each require controls appropriate to the specimen and assay.
ICH E6(R3) Guideline for Good Clinical Practice · 2024 Examination Content Outline: CPI Certification
49.How should budgets and contracts support reliable trial delivery?
Budget and contract review should establish whether the site can perform agreed responsibilities with adequate resources and clear arrangements. Relevant costs include screening failures, safety work, follow-up, data queries, storage and closure activities, not only completed visits. Financial arrangements should not distort participant selection or safety decisions. Investigators should identify mismatches between required work and available support before activation rather than rely on clinical staff to absorb unplanned obligations indefinitely.
Apply it
A proposed budget pays only for randomized participants, although screening requires substantial specialist review. Quantify the expected screening workload and resolve resource support before accepting recruitment targets that the site cannot responsibly deliver with its existing staffing.
Common pitfall: A positive payment per completed visit does not establish an adequate study budget. Unfunded screening, safety and closure work can undermine sustained site capacity.
ICH E6(R3) Guideline for Good Clinical Practice · 2024 Examination Content Outline: CPI Certification
50.How can retention strategies reduce burden without creating pressure?
Retention improves when visit planning, communication and participant support address practical barriers without undermining voluntary participation. Investigators should understand transport, work, caregiving and procedure burdens and use protocol-compatible arrangements. Reminders and reimbursement should support access rather than pressure participants to remain despite concerns. When a visit is missed, the aim is respectful clarification and appropriate follow-up, including safety needs, not pursuit that disregards the participant's preferences or withdrawal rights.
Apply it
A participant repeatedly misses morning visits because of caregiving duties. Explore an allowed afternoon appointment or approved support arrangement, confirm willingness to continue, and preserve required assessment timing rather than threatening loss of routine clinical care.
Common pitfall: Retention success is not simply a high completion rate. Coercive contact or pressure to remain can damage voluntariness even when it reduces apparent dropout.
ICH E8(R1) — General Considerations for Clinical Studies · WMA Declaration of Helsinki — Ethical Principles for Medical Research Involving Human Participants
51.How should clinical coverage work outside scheduled trial visits?
Participant oversight requires clear arrangements for clinically relevant questions, urgent events and investigator absence. Participants and staff should know how to reach appropriate qualified support and when to seek emergency care. Coverage must connect clinical action with study communication and documentation without requiring participants to navigate organizational boundaries. A written contact list helps only if it is current, accessible and backed by people authorized and prepared to respond.
Apply it
A participant calls the study office on a holiday with a new concerning symptom. The coverage arrangement should direct them to appropriate care and qualified study assessment, with subsequent documentation and reporting, rather than an unattended administrative voicemail.
Common pitfall: Providing a telephone number is not equivalent to providing coverage. Response capability, escalation and absence arrangements must function when the participant actually needs assistance.
52.What makes site close-out operationally complete?
Close-out reconciles remaining responsibilities, including participant follow-up, product disposition, unresolved data issues, essential records and future access arrangements. It should identify who retains records, handles later requests and receives relevant safety or administrative communications. A final monitor visit does not automatically establish completion of every obligation. Investigators should confirm that open items have documented owners and that closure does not leave participants or records without an appropriate continuing pathway.
Apply it
The last participant completes treatment, but returned product remains unreconciled and several source queries are open. Resolve or assign these issues, confirm follow-up and retention arrangements, and document completion rather than closing solely because no further dosing is planned.
Common pitfall: The last treatment visit and site close-out are different milestones. Product, data, participant care and record-access obligations can continue after treatment has ended.
Data Management13/100 allocation (13%)
53.What makes source data adequate to reconstruct trial conduct?
Source data are the original observations or appropriately documented records needed to understand and verify trial activities. Adequate records identify what occurred, when, for whom and by whom, with sufficient context for important decisions. Source can be electronic and may originate directly in a study system. Investigators should define where relevant information first resides and ensure that transcription or summaries do not obscure the underlying evidence supporting eligibility, treatment and outcomes.
Apply it
An eligibility worksheet says all criteria are met, but the qualifying test value and date are absent from accessible records. Obtain the supporting source or document the gap; the conclusion alone does not let a reviewer reconstruct eligibility.
Common pitfall: A completed checkbox can record a decision without preserving its basis. Source adequacy depends on reconstructable evidence, not merely the presence of a signed worksheet.
54.How should CRF review reconcile data with clinical records?
CRF or eCRF review should assess whether reported data are accurate, complete, consistent and supported by appropriate records. Transcription checks are important, but clinical coherence also matters: dates, adverse events, concomitant treatment and discontinuation reasons should tell a compatible story. Investigator review should be meaningful and timely for the data concerned. Signing a completed form does not relieve the site of investigating discrepancies or supplying relevant missing information.
Apply it
A discharge summary documents an admission, but the eCRF lists no serious event and shows uninterrupted outpatient treatment. Reconcile the records and assess clinical and reporting implications before approving the form as complete and accurate.
Common pitfall: Agreement between two copied fields does not prove correctness if both derive from the same erroneous entry. Review should connect reported data to reliable supporting information.
55.How should data corrections preserve trustworthiness?
Corrections should preserve the original information or its traceable history, identify the person making the change and record timing and reasons when needed. Electronic systems should provide appropriate audit trails for relevant changes. The aim is an understandable account of how the record evolved, not a visually perfect final entry. Investigators should distinguish a justified correction supported by evidence from an undocumented alteration made to align data with expectations.
Apply it
A transposed laboratory value is discovered after entry. Correct it against the verified report through the authorized process, preserving the original value and change history rather than deleting the earlier record and entering an untraceable replacement.
Common pitfall: Erasing the original entry removes evidence needed to understand the correction. A cleaner-looking record can be less trustworthy when its history is no longer available.
56.Which controls make electronic access attributable and appropriate?
Electronic access should match authorized responsibilities and permit actions to be attributed to the actual user. Individual accounts, appropriate permissions, timely access removal and relevant training support this goal. Shared credentials obscure who entered or approved data and can expose information beyond the user's role. System suitability also includes reliable operation and appropriate safeguards for the intended use. Investigators should understand their responsibilities even when the sponsor provides the platform.
Apply it
A departing coordinator's account remains active, and the replacement is asked to use it temporarily. Arrange a properly authorized individual account and remove obsolete access so new entries remain attributable to the person who actually performs them.
Common pitfall: Convenient credential sharing undermines attribution even if every user is trustworthy. Sponsor ownership of the system does not excuse inappropriate account use at the site.
57.How does coding protect confidentiality without making data anonymous?
Participant codes reduce unnecessary direct identification, while a separately protected linkage record allows authorized reidentification when required. Coded data are not necessarily anonymous because the identity can still be recovered through the key or other information. Access, transfer and storage controls remain important. Investigators should disclose only information appropriate to the purpose and understand how combinations of indirect identifiers can create confidentiality risks even when names are absent.
Apply it
A site sends a coded dataset together with the participant identification key in the same unrestricted folder. Separate and restrict the linkage information, review access and address the exposure; replacing names with codes did not protect identities in this arrangement.
Common pitfall: Removing names alone does not guarantee anonymity. A linkage key or distinctive combination of details may still permit identification and requires appropriate protection.
ICH E6(R3) Guideline for Good Clinical Practice · WMA Declaration of Helsinki — Ethical Principles for Medical Research Involving Human Participants
58.How should data queries be resolved without inventing information?
Query resolution should clarify discrepancies using available evidence and appropriately documented follow-up. Staff should distinguish a recoverable transcription error from information that was never collected or cannot now be verified. Timeliness matters, but rapid closure is not a reason to guess, backdate or select the value most favorable to the study. When uncertainty remains, document it through the appropriate process and assess effects on safety, eligibility or analysis.
Apply it
A query requests an exact symptom-onset time, but source notes record only the date and the participant cannot recall more precisely. Report the available information and uncertainty rather than inventing noon to make the field appear complete.
Common pitfall: A resolved query is not necessarily a truthful query. Completeness obtained by guessing can introduce false precision and conceal limitations important to clinical or statistical interpretation.
59.How do essential records and version control demonstrate compliant conduct?
Essential records collectively permit evaluation of trial conduct and the quality of resulting information. They include evidence of relevant approvals, responsibilities, training and key study activities, with content appropriate to the trial. Version control connects the procedures actually used with their authorized versions and implementation dates. Filing the newest document alone is insufficient when earlier conduct must be reconstructed. Records should remain identifiable, accessible and protected throughout their required lifecycle.
Apply it
Two consent versions are in circulation, but the site cannot establish when the newer version became effective. Reconstruct approval and implementation history, identify affected participants and assess whether the correct information and consent process were used.
Common pitfall: Replacing an old document with the latest copy can destroy useful history. Retain the version trail needed to explain which requirements governed earlier trial activities.
60.How should records remain usable throughout retention, and when may retention end?
Under E6(R3) section 2.12.12, retain records for the applicable regulatory period or until the sponsor states that they are no longer needed, whichever is longer. Sponsor release does not shorten an unexpired regulatory period, and expiry of that period does not end retention while the sponsor still needs the records. Throughout retention, records must remain protected, accessible and readable. Electronic archiving should preserve necessary metadata and audit trails and address format changes and recovery. Confirm that all retention obligations are satisfied before authorizing destruction.
Apply it
A site plans to close its electronic system subscription after study completion. Establish and verify a readable archive with necessary context and clear access responsibility. If the regulatory period has expired but the sponsor has not stated that the records are no longer needed, continue retaining them.
Common pitfall: An unreadable backup does not meet the purpose of retention. Neither sponsor release alone nor expiry of the regulatory period alone permits destruction when the other retention condition still requires the records.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give greatest attention to Ethical and Safety Considerations and Clinical Trial Operations, while maintaining coverage of every official domain and task statement.
- Separate seriousness, severity, causality and expectedness. Distinguish immediate investigator SAE notification from sponsor SUSAR reporting and its E2A seven-day, additional eight-day and fifteen-day timelines.
- Practise distinguishing treatment discontinuation, intercurrent events, missing observations and withdrawal of consent.
- Connect investigator delegation to qualification, supervision, participant care and meaningful review of data.
- Trace product movements, storage decisions, assignment controls and participant use without assuming that balanced inventory proves correct administration.
- Use the current E6(R3) framework and distinguish international principles from jurisdiction-specific legal rules.
- Interpret study conclusions through endpoints, confidence intervals, noninferiority margins and the prespecified estimand rather than significance labels alone.
A practical preparation plan
1. Map the full outline
Read the official 2024 CPI outline and map each knowledge area and task statement to evidence of your understanding. Use the 60 concepts as selected teaching units, then identify official tasks that need additional study.
2. Build a guideline decision map
Use E6(R3) for investigator conduct and records, E2A for safety definitions and sponsor expedited reporting, E8(R1) for development and feasibility, E9 and E9(R1) for design and interpretation, E11(R1) for pediatric issues, and Helsinki for ethical principles.
3. Work through participant journeys
Follow a hypothetical participant from prescreening through consent, eligibility, assignment, product use, safety review, discontinuation and follow-up. At each transition, identify the responsible role, required evidence and escalation route.
4. Practise operational reconciliation
Reconcile a product ledger, review a temperature excursion, investigate a missed endpoint and construct a CAPA plan. Explain the difference between fixing the immediate record and preventing the underlying failure.
5. Use drills diagnostically
Complete the 20 questions before reading their explanations. For each missed item, explain why every alternative is weaker, revisit the cited reference and answer a related flashcard without looking.
6. Reassess by domain and task
Allocate review approximately to the published domain weights, then increase time for demonstrated weaknesses. Finish by checking the complete official outline and current issuer information; a short practice score does not establish examination readiness.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- CPI Certification — ACRP
- The Academy — ACRP
- 2024 Examination Content Outline: CPI Certification
- Frequently Asked Questions — ACRP
- CPI Certification as Predictor of Clinical Investigators' Regulatory Compliance
- CPI Certification Guide — March 2009
- Clinical Researcher, February 2015 — One Word and One World of Difference
- ICH E6(R3) Guideline for Good Clinical Practice
- ICH E2A — Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
- ICH E8(R1) — General Considerations for Clinical Studies
- ICH E9 — Statistical Principles for Clinical Trials
- ICH E9(R1) — Addendum on Estimands and Sensitivity Analysis
- ICH E11(R1) — Clinical Investigation of Medicinal Products in the Pediatric Population
- WMA Declaration of Helsinki — Ethical Principles for Medical Research Involving Human Participants
- Global Certification in Pharmacy — Pharma Research
- The Society of Clinical Research Professional — SCRP
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.